CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed
A Phase 1 Study of CC-486 Plus Nivolumab in Patients With Hodgkin Lymphoma Refractory to PD-1 Therapy
Sponsor: City of Hope Medical Center
This PHASE1 trial investigates Recurrent Classic Hodgkin Lymphoma and Refractory Classic Hodgkin Lymphoma and is currently ongoing. City of Hope Medical Center leads this study, which shows 10 recorded versions since 2022 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Jul 2025 — Present [monthly]
Active Not Recruiting PHASE1
-
Oct 2024 — Jul 2025 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Feb 2024 — Jul 2024 [monthly]
Recruiting PHASE1
▶ Show 5 earlier versions
-
Aug 2023 — Feb 2024 [monthly]
Recruiting PHASE1
Status: Active Not Recruiting → Recruiting
-
Jul 2023 — Aug 2023 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Apr 2023 — Jul 2023 [monthly]
Recruiting PHASE1
-
Apr 2022 — Apr 2023 [monthly]
Recruiting PHASE1
-
Jan 2022 — Apr 2022 [monthly]
Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- City of Hope Medical Center
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .